lncRNA HEIH, an indicator of high malignancy and poor prognosis, functions as an oncogene in breast cancer

Chen,Cheng; Gu,Cheng; Ren,Qian; Ding,Fanghui; Pan,Qing; Niu,Yicong; Ma,Dachang; Wu,Li

doi:10.3892/mmr.2020.11355

lncRNA HEIH, an indicator of high malignancy and poor prognosis, functions as an oncogene in breast cancer

Authors:
- Cheng Chen
- Cheng Gu
- Qian Ren
- Fanghui Ding
- Qing Pan
- Yicong Niu
- Dachang Ma
- Li Wu
View Affiliations

Affiliations: Department of Galactophore, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Neurology, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China, Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China
Published online on: July 23, 2020 https://doi.org/10.3892/mmr.2020.11355
Pages: 2869-2877
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNA high expression in hepatocellular carcinoma (lncRNA HEIH) acts as an oncogene in multiple tumors, including hepatocellular carcinoma, colorectal cancer, melanoma and non‑small cell lung cancer. However, the role of HEIH in breast cancer remains unknown. The present study focused on the clinical significance and biological function of HEIH in breast cancer. Specifically, the expression levels of HEIH in breast cancer tissues and breast cancer cell lines were investigated. The results indicated high expression levels of HEIH in human breast cancer tissues, and its expression was positively associated with malignancy status and poor disease prognosis. High expression levels of HEIH were detected in the breast cancer cell lines, including MCF‑7, SK‑BR‑3, MDA‑MB‑231 and MDA‑MB‑468. These data were consistent with those derived from the in vivo study. Therefore, small interfering RNA was used to knockdown HEIH expression in order to explore whether HEIH exhibits an oncogenic function in breast cancer. Following HEIH knockdown, the proliferative and metastatic activity of MDA‑MB‑231 cells was decreased, whereas the induction of cell apoptosis was increased. These results suggested the oncogenic role of HEIH in breast cancer and the potential application of HEIH as an index of malignancy and poor prognosis in breast cancer.

View Figures

View References

1	Gardezi SJS, Elazab A, Lei B and Wang T: Breast cancer detection and diagnosis using mammographic data: Systematic review. J Med Internet Res. 21:28692019. View Article : Google Scholar
2	Merino Bonilla JA, Torres Tabanera M and Ros Mendoza LH: Breast cancer in the 21st century: From early detection to new therapies. Radiologia. 59:368–379. 2017. View Article : Google Scholar : PubMed/NCBI
3	Kumar M, DeVaux RS and Herschkowitz JI: Molecular and cellular changes in breast cancer and new roles of lncRNAs in breast cancer initiation and progression. Prog Mol Biol Transl Sci. 144:563–586. 2016. View Article : Google Scholar : PubMed/NCBI
4	Bhan A, Soleimani M and Mandal SS: Long noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981. 2017. View Article : Google Scholar : PubMed/NCBI
5	Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, Zhu N, Zhou WP, Yang GS, Wang YZ, et al: Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology. 54:1679–1689. 2011. View Article : Google Scholar : PubMed/NCBI
6	Ma Y, Cao D, Li G, Hu J, Liu X and Liu J: Silence of lncRNA HEIH suppressed liver cancer cell growth and metastasis through miR-199a-3p/mTOR axis. J Cell Biochem. 120:17757–17766. 2019. View Article : Google Scholar : PubMed/NCBI
7	Cui C, Zhai D, Cai L, Duan Q, Xie L and Yu J: Long noncoding RNA HEIH promotes colorectal cancer tumorigenesis via counteracting miR-939mediated transcriptional repression of Bcl-xL. Cancer Res Treat. 50:992–1008. 2018. View Article : Google Scholar : PubMed/NCBI
8	Zhao H, Xing G, Wang Y, Luo Z, Liu G and Meng H: Long noncoding RNA HEIH promotes melanoma cell proliferation, migration and invasion via inhibition of miR-200b/a/429. Biosci Rep. 37:BSR201706822017. View Article : Google Scholar : PubMed/NCBI
9	Jia K, Chen F and Xu L: Long noncoding RNA HEIH promotes the proliferation and metastasis of non-small cell lung cancer. J Cell Biochem. 120:3529–3538. 2019. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Li WQ, Li XH, Wu YH, Du J, Wang AP, Li D and Li YJ: Role of eukaryotic translation initiation factors 3a in hypoxia-induced right ventricular remodeling of rats. Life Sci. 144:61–68. 2016. View Article : Google Scholar : PubMed/NCBI
12	Ling H, Vincent K, Pichler M, Fodde R, Berindan-Neagoe I, Slack FJ and Calin GA: Junk DNA and the long non-coding RNA twist in cancer genetics. Oncogene. 34:5003–5011. 2015. View Article : Google Scholar : PubMed/NCBI
13	Ling H, Krassnig L, Bullock MD and Pichler M: MicroRNAs in testicular cancer diagnosis and prognosis. Urol Clin North Am. 43:127–134. 2016. View Article : Google Scholar : PubMed/NCBI
14	Thomas J, Ohtsuka M, Pichler M and Ling H: MicroRNAs: Clinical relevance in colorectal cancer. Int J Mol Sci. 16:28063–28076. 2015. View Article : Google Scholar : PubMed/NCBI
15	Troppan K, Wenzl K, Deutsch A, Ling H, Neumeister P and Pichler M: MicroRNAs in diffuse large B-cell lymphoma: Implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res. 34:557–564. 2014.PubMed/NCBI
16	Youness RA and Gad MZ: Long non-coding RNAs: Functional regulatory players in breast cancer. Noncoding RNA Res. 4:36–44. 2019. View Article : Google Scholar : PubMed/NCBI
17	Xu N, Wang F, Lv M and Cheng L: Microarray expression profile analysis of long non-coding RNAs in human breast cancer: A study of Chinese women. Biomed Pharmacother. 69:221–227. 2015. View Article : Google Scholar : PubMed/NCBI
18	Shen X, Xie B, Ma Z, Yu W, Wang W, Xu D, Yan X, Chen B, Yu L, Li J, et al: Identification of novel long non-coding RNAs in triple-negative breast cancer. Oncotarget. 6:21730–21739. 2015. View Article : Google Scholar : PubMed/NCBI
19	Yang F, Lyu S, Dong S, Liu Y, Zhang X and Wang O: Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics. OncoTargets Ther. 9:761–772. 2016. View Article : Google Scholar
20	Ma D, Chen C, Wu J, Wang H and Wu D: Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer. Breast Cancer. 26:74–83. 2019. View Article : Google Scholar : PubMed/NCBI
21	Park SY, Choi JH and Nam JS: Targeting cancer stem cells in triple-negative breast cancer. Cancers (Basel). 11:9652019. View Article : Google Scholar
22	McCann KE, Hurvitz SA and McAndrew N: Advances in targeted therapies for triple-negative breast cancer. Drugs. 79:1217–1230. 2019. View Article : Google Scholar : PubMed/NCBI
23	Saleh R, Taha RZ, Sasidharan Nair V, Alajez NM and Elkord E: PD-L1 blockade by atezolizumab downregulates signaling pathways associated with tumor growth, metastasis, and hypoxia in human triple negative breast cancer. Cancers (Basel). 11:10502019. View Article : Google Scholar